Clinical trials: Myelodysplastic Syndromes(MDS)
Metastatic Cancer, Cancer, Breast
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Sarcopenia is defined as reduction in muscle mass and function according to the criteria of the European Working Group on Sarcopenia in older people.
- Conditions
- Metastatic Cancer, Cancer, Breast, Cancer Colon, Cancer, Rectum
- Trial name
- SPACE2 (NCT05154474)
- Testing
- Standard
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Weprom
Acute Leukemia, Myelodysplasia
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis to standard tacrolimus and methotrexate…
- Trial name
- NCT02345850
- Testing
- Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide
- Where
- 28 sites in United States
- Volunteers
- 346 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia
Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
The aim of the study is to improve the accuracy of diagnosis for children and adolescents with MDS by a standardized review of morphology and standardized cytogenetic and molecular analysis.
- Trial name
- EWOG MDS 2006 (NCT00662090)
- Where
- Germany
- Volunteers
- 260 people
- Sponsor
- University Hospital Freiburg
Acute Myeloid Leukemia, Myelodysplastic Syndrome
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: SL-401 Azacitidine Venetoclax
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT03113643
- Testing
- Azacitidine, SL-401, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Dana-Farber Cancer Institute
Lower-risk Myelodysplastic Syndromes
Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan
The purpose of this study is to describe the treatment patterns, clinical outcomes, healthcare resource utilization (HCRU) and medical costs of lower-risk myelodysplastic syndromes patients in Japan.
- Trial name
- NCT06298643
- Testing
- Red blood cell transfusion
- Where
- Japan
- Volunteers
- 177 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- AML-MDS 001 (NCT07270978)
- Testing
- CD33 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Myelodysplastic Syndrome
Erlotinib in Higher Risk Myelodysplastic Syndrome
The aim of this study is to evaluate the toxicity and therapeutic efficacy of erlotinib in high-risk myelodysplastic syndrome (MDS) patients (with at least 10% of bone marrow blasts) ineligible for or having failed intensive…
- Trial name
- NCT01085838
- Testing
- Erlotinib
- Where
- 14 sites in France
- Volunteers
- 30 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Chronic Myeloproliferative Disorders, Leukemia
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00290641
- Testing
- filgrastim, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelodysplastic Syndrome, MDS
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
Revlimid® (Lenalidomide) is indicated for a type of blood cancer, myelodysplastic syndrome (MDS), at 10mg for a specific type of myelodysplastic syndrome with a genetic abnormality called "deletion 5q" in Low and Intermediate-1…
- Conditions
- Myelodysplastic Syndrome, MDS, Low to Intermediate-1 MDS, Non-deletion 5q
- Trial name
- NCT00699842
- Testing
- Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Taiho (formerly Astex)-sponsored clinical study of ASTX727 (including, but not limited…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04093570
- Testing
- ASTX727
- Where
- 47 sites in United States, Armenia and 11 more
- Volunteers
- 332 people
- Sponsor
- Taiho Oncology, Inc.
Myelodysplastic Syndrome (MDS)
A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
The primary objective of the study is to determine the response rate according to the International Working Group Response criteria for the combination of FF-10501-01 and azacitidine in patients previously untreated with…
- Trial name
- NCT03486353
- Testing
- FF-10501-01, Azacitidine
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has come back (relapsed) or that does…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Trial name
- NCT03672539
- Testing
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
The main objective of this work is to conduct a clinical study for the development and application of a vaccine with autologous dendritic cells submitted to electroporation with Wilm's tumor 1 (WT1) messenger ribonucleic acid…
- Trial name
- NCT03083054
- Testing
- Autologous dendritic cells electroporated with WT1 mRNA
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- University of Campinas, Brazil
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative…
- Conditions
- Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT06523556
- Testing
- Axatilimab, Azacitidine, Biospecimen Collection
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Uma Borate
Myelodysplastic Syndrome (MDS)
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)
This study assessed the efficacy and safety of LBH589 as single agent and in combination with ESA in red blood cell transfusion-dependent Low and Int-1 MDS patients being either refractory to ESA or with a low probability of…
- Trial name
- GEPARD (NCT01034657)
- Testing
- LBH589, Epoetin Alfa
- Where
- 12 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
The reconstitution of a functioning immune system after allogeneic stem cell transplantation takes months to years. Particularly memory B-lymphocytes reconstitute poorly with the current conditioning regimes.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non Hodgkin's Lymphoma
- Trial name
- B-cell therapy (NCT02007811)
- Testing
- allogeneic donor derived B-lymphocytes
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
Phase I trial to study the effectiveness of PS-341 in treating patients who have refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia in blast phase, or myelodysplastic syndrome.
- Conditions
- Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00005064
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
AML, MDS
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
This is a Phase 1/2a dose-escalation study of E6201, a dual mitogen-activated protein kinase/extracellular-signal regulated kinase 1 (MEK1) and FMS-like tyrosine kinase 3 (FLT3) inhibitor, in subjects with advanced hematologic…
- Conditions
- AML, MDS, CMML
- Trial name
- NCT02418000
- Testing
- E6201
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spirita Oncology, LLC
Leukemia, Myelodysplastic Syndromes
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00077558
- Testing
- fludarabine phosphate, triapine
- Where
- 4 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Myelodysplastic Syndromes
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398047
- Testing
- Azacitadine and Hematopoietic Growth Factors
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Wake Forest University Health Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.